Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million Portfolio News / Karina Tin September 17, 2024 Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million Read More »
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate Portfolio News / Karina Tin September 10, 2024 Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate Read More »
Kallyope Announces License Agreement with Novo Nordisk Portfolio News / Karina Tin September 10, 2024 Kallyope Announces License Agreement with Novo Nordisk Read More »
Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion Portfolio News / Karina Tin September 4, 2024 Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion Read More »
Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies Portfolio News / Karina Tin September 3, 2024 Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies Read More »
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates Portfolio News / Karina Tin August 12, 2024 ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates Read More »
Atavistik Bio Strengthens Leadership Team with Appointment of Paul Bruno, Ph.D. as Chief Business Officer Portfolio News / Karina Tin August 12, 2024 Atavistik Bio Strengthens Leadership Team with Appointment of Paul Bruno, Ph.D. as Chief Business Officer Read More »
Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Portfolio News / Karina Tin August 8, 2024 Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Read More »
RAPT Therapeutics Reports Second Quarter 2024 Financial Results Portfolio News / Karina Tin August 8, 2024 RAPT Therapeutics Reports Second Quarter 2024 Financial Results Read More »
Tr1X Announces FDA Clearance of IND Application for TRX103, an Allogeneic Engineered Tr1 Treg Cell Therapy for Treatment-Refractory Crohn’s Disease Portfolio News / Karina Tin August 7, 2024 Tr1X Announces FDA Clearance of IND Application for TRX103, an Allogeneic Engineered Tr1 Treg Cell Therapy for Treatment-Refractory Crohn’s Disease Read More »
